Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1998 Feb 15;101(4):877–889. doi: 10.1172/JCI1509

Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents.

A Koenig 1, K Norgard-Sumnicht 1, R Linhardt 1, A Varki 1
PMCID: PMC508636  PMID: 9466983

Abstract

The selectins are calcium-dependent C-type lectins that bind certain sialylated, fucosylated, sulfated glycoprotein ligands. L-selectin also recognizes endothelial proteoglycans in a calcium-dependent manner, via heparan sulfate (HS) glycosaminoglycan chains enriched in unsubstituted glucosamine units. We now show that these HS chains can also bind P-selectin, but not E-selectin. However, while L-selectin binding requires micromolar levels of free calcium, P-selectin recognition is largely divalent cation-independent. Despite this, HS chains bound to P-selectin are eluted by ethylenediamine tetraacetic acid (EDTA), but only at high concentrations. Porcine intestinal mucosal (mast cell-derived) heparin (PIM-heparin) shows similar properties, with no binding to E-selectin, calcium-dependent binding of a subfraction to L-selectin and to P-selectin, and calcium-independent binding of a larger fraction to P-selectin, the latter being disrupted by high EDTA concentrations. Analysis of defined heparin fragment pools shows a size dependence for interaction, with tetradecasaccharides showing easily detectable binding to L- and P-selectin affinity columns. L-selectin binding fragments include more heavily sulfated and epimerized regions and, as with the endothelial HS chains, they are enriched in free amino groups. The P-selectin binding component includes this fraction as well as some less highly modified regions. Thus, endothelium-derived HS chains and mast cell-derived heparins could play a role in modulating the biology of selectins in vivo. Notably, P- and L-selectin binding to sialyl-Lewisx and to HL-60 cells (which are known to carry the native ligand PSGL-1) is inhibited by unfractionated pharmaceutical heparin preparations at concentrations 12-50-fold lower than those recommended for effective anticoagulation in vivo. In contrast, two low molecular weight heparins currently considered as clinical replacements for unfractionated heparin are much poorer inhibitors. Thus, patients undergoing heparin therapy for other reasons may be experiencing clinically significant inhibition of L- and P-selectin function, and the current switchover to low-molecular weight heparins may come at some loss of this effect. Low-dose unfractionated heparin should be investigated as a treatment option for acute and chronic diseases in which P- and L-selectin play pathological roles.

Full Text

The Full Text of this article is available as a PDF (286.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albelda S. M., Smith C. W., Ward P. A. Adhesion molecules and inflammatory injury. FASEB J. 1994 May;8(8):504–512. [PubMed] [Google Scholar]
  2. Aruffo A., Dietsch M. T., Wan H., Hellström K. E., Hellström I. Granule membrane protein 140 (GMP140) binds to carcinomas and carcinoma-derived cell lines. Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2292–2296. doi: 10.1073/pnas.89.6.2292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Aruffo A., Kolanus W., Walz G., Fredman P., Seed B. CD62/P-selectin recognition of myeloid and tumor cell sulfatides. Cell. 1991 Oct 4;67(1):35–44. doi: 10.1016/0092-8674(91)90570-o. [DOI] [PubMed] [Google Scholar]
  4. Berg E. L., Magnani J., Warnock R. A., Robinson M. K., Butcher E. C. Comparison of L-selectin and E-selectin ligand specificities: the L-selectin can bind the E-selectin ligands sialyl Le(x) and sialyl Le(a). Biochem Biophys Res Commun. 1992 Apr 30;184(2):1048–1055. doi: 10.1016/0006-291x(92)90697-j. [DOI] [PubMed] [Google Scholar]
  5. Berg E. L., Robinson M. K., Mansson O., Butcher E. C., Magnani J. L. A carbohydrate domain common to both sialyl Le(a) and sialyl Le(X) is recognized by the endothelial cell leukocyte adhesion molecule ELAM-1. J Biol Chem. 1991 Aug 15;266(23):14869–14872. [PubMed] [Google Scholar]
  6. Bevilacqua M. P., Nelson R. M., Mannori G., Cecconi O. Endothelial-leukocyte adhesion molecules in human disease. Annu Rev Med. 1994;45:361–378. doi: 10.1146/annurev.med.45.1.361. [DOI] [PubMed] [Google Scholar]
  7. Bevilacqua M. P., Nelson R. M. Selectins. J Clin Invest. 1993 Feb;91(2):379–387. doi: 10.1172/JCI116210. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Boneu B. Glycosaminoglycans: clinical use. Semin Thromb Hemost. 1996;22(2):209–212. doi: 10.1055/s-2007-999010. [DOI] [PubMed] [Google Scholar]
  9. Buerke M., Weyrich A. S., Zheng Z., Gaeta F. C., Forrest M. J., Lefer A. M. Sialyl Lewisx-containing oligosaccharide attenuates myocardial reperfusion injury in cats. J Clin Invest. 1994 Mar;93(3):1140–1148. doi: 10.1172/JCI117066. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Butcher E. C., Picker L. J. Lymphocyte homing and homeostasis. Science. 1996 Apr 5;272(5258):60–66. doi: 10.1126/science.272.5258.60. [DOI] [PubMed] [Google Scholar]
  11. Coccheri S. Low molecular weight heparins: an introduction. Haemostasis. 1990;20 (Suppl 1):74–80. doi: 10.1159/000216163. [DOI] [PubMed] [Google Scholar]
  12. Commerford P. J. Heparin after acute myocardial infarction. Cardiovasc Drugs Ther. 1997 Apr;11(2):101–109. doi: 10.1023/a:1007724628936. [DOI] [PubMed] [Google Scholar]
  13. Crocker P. R., Feizi T. Carbohydrate recognition systems: functional triads in cell-cell interactions. Curr Opin Struct Biol. 1996 Oct;6(5):679–691. doi: 10.1016/s0959-440x(96)80036-4. [DOI] [PubMed] [Google Scholar]
  14. Dawes J. Interactions of heparins in the vascular environment. Haemostasis. 1993 Mar;23 (Suppl 1):212–219. doi: 10.1159/000216930. [DOI] [PubMed] [Google Scholar]
  15. Desai U. R., Wang H. M., Linhardt R. J. Specificity studies on the heparin lyases from Flavobacterium heparinum. Biochemistry. 1993 Aug 17;32(32):8140–8145. doi: 10.1021/bi00083a012. [DOI] [PubMed] [Google Scholar]
  16. El Habbal M. H., Smith L., Elliott M. J., Strobel S. Effect of heparin anticoagulation on neutrophil adhesion molecules and release of IL8: C3 is not essential. Cardiovasc Res. 1995 Nov;30(5):676–681. doi: 10.1016/0008-6363(95)00069-0. [DOI] [PubMed] [Google Scholar]
  17. Fareed J., Walenga J. M., Hoppensteadt D., Huan X., Racanelli A. Comparative study on the in vitro and in vivo activities of seven low-molecular-weight heparins. Haemostasis. 1988;18 (Suppl 3):3–15. doi: 10.1159/000215861. [DOI] [PubMed] [Google Scholar]
  18. Flynn D. M., Buda A. J., Jeffords P. R., Lefer D. J. A sialyl Lewis(x)-containing carbohydrate reduces infarct size: role of selectins in myocardial reperfusion injury. Am J Physiol. 1996 Nov;271(5 Pt 2):H2086–H2096. doi: 10.1152/ajpheart.1996.271.5.H2086. [DOI] [PubMed] [Google Scholar]
  19. Foxall C., Watson S. R., Dowbenko D., Fennie C., Lasky L. A., Kiso M., Hasegawa A., Asa D., Brandley B. K. The three members of the selectin receptor family recognize a common carbohydrate epitope, the sialyl Lewis(x) oligosaccharide. J Cell Biol. 1992 May;117(4):895–902. doi: 10.1083/jcb.117.4.895. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Freedman M. D. Low molecular weight heparins: an emerging new class of glycosaminoglycan antithrombotics. J Clin Pharmacol. 1991 Apr;31(4):298–306. doi: 10.1002/j.1552-4604.1991.tb03709.x. [DOI] [PubMed] [Google Scholar]
  21. Frenette P. S., Wagner D. D. Insights into selectin function from knockout mice. Thromb Haemost. 1997 Jul;78(1):60–64. [PubMed] [Google Scholar]
  22. Furie B., Furie B. C. The molecular basis of platelet and endothelial cell interaction with neutrophils and monocytes: role of P-selectin and the P-selectin ligand, PSGL-1. Thromb Haemost. 1995 Jul;74(1):224–227. [PubMed] [Google Scholar]
  23. Geng J. G., Bevilacqua M. P., Moore K. L., McIntyre T. M., Prescott S. M., Kim J. M., Bliss G. A., Zimmerman G. A., McEver R. P. Rapid neutrophil adhesion to activated endothelium mediated by GMP-140. Nature. 1990 Feb 22;343(6260):757–760. doi: 10.1038/343757a0. [DOI] [PubMed] [Google Scholar]
  24. Geng J. G., Moore K. L., Johnson A. E., McEver R. P. Neutrophil recognition requires a Ca(2+)-induced conformational change in the lectin domain of GMP-140. J Biol Chem. 1991 Nov 25;266(33):22313–22318. [PubMed] [Google Scholar]
  25. Ginsberg J. S. Management of venous thromboembolism. N Engl J Med. 1996 Dec 12;335(24):1816–1828. doi: 10.1056/NEJM199612123352407. [DOI] [PubMed] [Google Scholar]
  26. Giuffrè L., Cordey A. S., Monai N., Tardy Y., Schapira M., Spertini O. Monocyte adhesion to activated aortic endothelium: role of L-selectin and heparan sulfate proteoglycans. J Cell Biol. 1997 Feb 24;136(4):945–956. doi: 10.1083/jcb.136.4.945. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Granger C. B., Hirsch J., Califf R. M., Col J., White H. D., Betriu A., Woodlief L. H., Lee K. L., Bovill E. G., Simes R. J. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation. 1996 Mar 1;93(5):870–878. doi: 10.1161/01.cir.93.5.870. [DOI] [PubMed] [Google Scholar]
  28. Graves B. J., Crowther R. L., Chandran C., Rumberger J. M., Li S., Huang K. S., Presky D. H., Familletti P. C., Wolitzky B. A., Burns D. K. Insight into E-selectin/ligand interaction from the crystal structure and mutagenesis of the lec/EGF domains. Nature. 1994 Feb 10;367(6463):532–538. doi: 10.1038/367532a0. [DOI] [PubMed] [Google Scholar]
  29. Hamano S., Nishiyama M., Komatsu H., Miyata H., Ikeda S., Sakuragawa N. Study of anticoagulant mechanism of low molecular weight heparin. Thromb Res. 1992 Mar 15;65(6):801–808. doi: 10.1016/0049-3848(92)90118-t. [DOI] [PubMed] [Google Scholar]
  30. Handa K., Nudelman E. D., Stroud M. R., Shiozawa T., Hakomori S. Selectin GMP-140 (CD62; PADGEM) binds to sialosyl-Le(a) and sialosyl-Le(x), and sulfated glycans modulate this binding. Biochem Biophys Res Commun. 1991 Dec 31;181(3):1223–1230. doi: 10.1016/0006-291x(91)92069-v. [DOI] [PubMed] [Google Scholar]
  31. Hemmerich S., Leffler H., Rosen S. D. Structure of the O-glycans in GlyCAM-1, an endothelial-derived ligand for L-selectin. J Biol Chem. 1995 May 19;270(20):12035–12047. doi: 10.1074/jbc.270.20.12035. [DOI] [PubMed] [Google Scholar]
  32. Hicke B. J., Watson S. R., Koenig A., Lynott C. K., Bargatze R. F., Chang Y. F., Ringquist S., Moon-McDermott L., Jennings S., Fitzwater T. DNA aptamers block L-selectin function in vivo. Inhibition of human lymphocyte trafficking in SCID mice. J Clin Invest. 1996 Dec 15;98(12):2688–2692. doi: 10.1172/JCI119092. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Hirsh J. Comparison of the relative efficacy and safety of low-molecular-weight heparin and unfractionated heparin for the treatment of venous thrombosis. Semin Thromb Hemost. 1996;22 (Suppl 2):7–30. [PubMed] [Google Scholar]
  34. Horne M. K., 3rd, Chao E. S. Heparin binding to resting and activated platelets. Blood. 1989 Jul;74(1):238–243. [PubMed] [Google Scholar]
  35. Horne M. K., 3rd Heparin binds normally to platelets digested with Streptomyces griseus protease. Thromb Res. 1991 Jan 15;61(2):155–158. doi: 10.1016/0049-3848(91)90242-o. [DOI] [PubMed] [Google Scholar]
  36. Hynes R. O., Wagner D. D. Genetic manipulation of vascular adhesion molecules in mice. J Clin Invest. 1996 Nov 15;98(10):2193–2195. doi: 10.1172/JCI119027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Jandik K. A., Gu K., Linhardt R. J. Action pattern of polysaccharide lyases on glycosaminoglycans. Glycobiology. 1994 Jun;4(3):289–296. doi: 10.1093/glycob/4.3.289. [DOI] [PubMed] [Google Scholar]
  38. Kansas G. S. Selectins and their ligands: current concepts and controversies. Blood. 1996 Nov 1;88(9):3259–3287. [PubMed] [Google Scholar]
  39. Koenig A., Jain R., Vig R., Norgard-Sumnicht K. E., Matta K. L., Varki A. Selectin inhibition: synthesis and evaluation of novel sialylated, sulfated and fucosylated oligosaccharides, including the major capping group of GlyCAM-1. Glycobiology. 1997 Feb;7(1):79–93. doi: 10.1093/glycob/7.1.79. [DOI] [PubMed] [Google Scholar]
  40. Lane D. A., Ryan K. The importance of anti-factor Xa and antithrombin activities of low molecular weight heparins. J Lab Clin Med. 1990 Aug;116(2):269–270. [PubMed] [Google Scholar]
  41. Larkin M., Ahern T. J., Stoll M. S., Shaffer M., Sako D., O'Brien J., Yuen C. T., Lawson A. M., Childs R. A., Barone K. M. Spectrum of sialylated and nonsialylated fuco-oligosaccharides bound by the endothelial-leukocyte adhesion molecule E-selectin. Dependence of the carbohydrate binding activity on E-selectin density. J Biol Chem. 1992 Jul 5;267(19):13661–13668. [PubMed] [Google Scholar]
  42. Lasky L. A. Selectin-carbohydrate interactions and the initiation of the inflammatory response. Annu Rev Biochem. 1995;64:113–139. doi: 10.1146/annurev.bi.64.070195.000553. [DOI] [PubMed] [Google Scholar]
  43. Leculier C., Benzerara O., Couprie N., Francina A., Lasne Y., Archimbaud E., Fiere D. Specific binding between human neutrophils and heparin. Br J Haematol. 1992 May;81(1):81–85. doi: 10.1111/j.1365-2141.1992.tb08176.x. [DOI] [PubMed] [Google Scholar]
  44. Lefer A. M. Role of selectins in myocardial ischemia-reperfusion injury. Ann Thorac Surg. 1995 Sep;60(3):773–777. doi: 10.1016/0003-4975(95)00424-J. [DOI] [PubMed] [Google Scholar]
  45. Lefer D. J., Flynn D. M., Phillips M. L., Ratcliffe M., Buda A. J. A novel sialyl LewisX analog attenuates neutrophil accumulation and myocardial necrosis after ischemia and reperfusion. Circulation. 1994 Nov;90(5):2390–2401. doi: 10.1161/01.cir.90.5.2390. [DOI] [PubMed] [Google Scholar]
  46. Lincoff A. M., Tcheng J. E., Califf R. M., Bass T., Popma J. J., Teirstein P. S., Kleiman N. S., Hattel L. J., Anderson H. V., Ferguson J. J. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators. Am J Cardiol. 1997 Feb 1;79(3):286–291. doi: 10.1016/s0002-9149(96)00749-7. [DOI] [PubMed] [Google Scholar]
  47. Lohse D. L., Linhardt R. J. Purification and characterization of heparin lyases from Flavobacterium heparinum. J Biol Chem. 1992 Dec 5;267(34):24347–24355. [PubMed] [Google Scholar]
  48. Lowe J. B., Ward P. A. Therapeutic inhibition of carbohydrate-protein interactions in vivo. J Clin Invest. 1997 Mar 1;99(5):822–826. doi: 10.1172/JCI119244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Malý P., Thall A., Petryniak B., Rogers C. E., Smith P. L., Marks R. M., Kelly R. J., Gersten K. M., Cheng G., Saunders T. L. The alpha(1,3)fucosyltransferase Fuc-TVII controls leukocyte trafficking through an essential role in L-, E-, and P-selectin ligand biosynthesis. Cell. 1996 Aug 23;86(4):643–653. doi: 10.1016/s0092-8674(00)80137-3. [DOI] [PubMed] [Google Scholar]
  50. Mammen E. F. Why low molecular weight heparin? Semin Thromb Hemost. 1990 Oct;16 (Suppl):1–4. [PubMed] [Google Scholar]
  51. Matsusako T., Muramatsu H., Shirahama T., Muramatsu T., Ohi Y. Expression of a carbohydrate signal, sialyl dimeric Le(x) antigen, is associated with metastatic potential of transitional cell carcinoma of the human urinary bladder. Biochem Biophys Res Commun. 1991 Dec 31;181(3):1218–1222. doi: 10.1016/0006-291x(91)92068-u. [DOI] [PubMed] [Google Scholar]
  52. McEver R. P., Cummings R. D. Perspectives series: cell adhesion in vascular biology. Role of PSGL-1 binding to selectins in leukocyte recruitment. J Clin Invest. 1997 Aug 1;100(3):485–491. doi: 10.1172/JCI119556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. McEver R. P., Moore K. L., Cummings R. D. Leukocyte trafficking mediated by selectin-carbohydrate interactions. J Biol Chem. 1995 May 12;270(19):11025–11028. doi: 10.1074/jbc.270.19.11025. [DOI] [PubMed] [Google Scholar]
  54. Mitsuoka C., Kawakami-Kimura N., Kasugai-Sawada M., Hiraiwa N., Toda K., Ishida H., Kiso M., Hasegawa A., Kannagi R. Sulfated sialyl Lewis X, the putative L-selectin ligand, detected on endothelial cells of high endothelial venules by a distinct set of anti-sialyl Lewis X antibodies. Biochem Biophys Res Commun. 1997 Jan 23;230(3):546–551. doi: 10.1006/bbrc.1996.6012. [DOI] [PubMed] [Google Scholar]
  55. Mulligan M. S., Lowe J. B., Larsen R. D., Paulson J., Zheng Z. L., DeFrees S., Maemura K., Fukuda M., Ward P. A. Protective effects of sialylated oligosaccharides in immune complex-induced acute lung injury. J Exp Med. 1993 Aug 1;178(2):623–631. doi: 10.1084/jem.178.2.623. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Nakamori S., Kameyama M., Imaoka S., Furukawa H., Ishikawa O., Sasaki Y., Izumi Y., Irimura T. Involvement of carbohydrate antigen sialyl Lewis(x) in colorectal cancer metastasis. Dis Colon Rectum. 1997 Apr;40(4):420–431. doi: 10.1007/BF02258386. [DOI] [PubMed] [Google Scholar]
  57. Nakamori S., Kameyama M., Imaoka S., Furukawa H., Ishikawa O., Sasaki Y., Kabuto T., Iwanaga T., Matsushita Y., Irimura T. Increased expression of sialyl Lewisx antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. Cancer Res. 1993 Aug 1;53(15):3632–3637. [PubMed] [Google Scholar]
  58. Needham L. K., Schnaar R. L. The HNK-1 reactive sulfoglucuronyl glycolipids are ligands for L-selectin and P-selectin but not E-selectin. Proc Natl Acad Sci U S A. 1993 Feb 15;90(4):1359–1363. doi: 10.1073/pnas.90.4.1359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Nelson R. M., Cecconi O., Roberts W. G., Aruffo A., Linhardt R. J., Bevilacqua M. P. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood. 1993 Dec 1;82(11):3253–3258. [PubMed] [Google Scholar]
  60. Nelson R. M., Dolich S., Aruffo A., Cecconi O., Bevilacqua M. P. Higher-affinity oligosaccharide ligands for E-selectin. J Clin Invest. 1993 Mar;91(3):1157–1166. doi: 10.1172/JCI116275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Nelson R. M., Venot A., Bevilacqua M. P., Linhardt R. J., Stamenkovic I. Carbohydrate-protein interactions in vascular biology. Annu Rev Cell Dev Biol. 1995;11:601–631. doi: 10.1146/annurev.cb.11.110195.003125. [DOI] [PubMed] [Google Scholar]
  62. Norgard-Sumnicht K. E., Varki N. M., Varki A. Calcium-dependent heparin-like ligands for L-selectin in nonlymphoid endothelial cells. Science. 1993 Jul 23;261(5120):480–483. doi: 10.1126/science.7687382. [DOI] [PubMed] [Google Scholar]
  63. Norgard-Sumnicht K., Varki A. Endothelial heparan sulfate proteoglycans that bind to L-selectin have glucosamine residues with unsubstituted amino groups. J Biol Chem. 1995 May 19;270(20):12012–12024. doi: 10.1074/jbc.270.20.12012. [DOI] [PubMed] [Google Scholar]
  64. Norgard K. E., Han H., Powell L., Kriegler M., Varki A., Varki N. M. Enhanced interaction of L-selectin with the high endothelial venule ligand via selectively oxidized sialic acids. Proc Natl Acad Sci U S A. 1993 Feb 1;90(3):1068–1072. doi: 10.1073/pnas.90.3.1068. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Norgard K. E., Moore K. L., Diaz S., Stults N. L., Ushiyama S., McEver R. P., Cummings R. D., Varki A. Characterization of a specific ligand for P-selectin on myeloid cells. A minor glycoprotein with sialylated O-linked oligosaccharides. J Biol Chem. 1993 Jun 15;268(17):12764–12774. [PubMed] [Google Scholar]
  66. Nurmohamed M. T., ten Cate H., ten Cate J. W. Low molecular weight heparin(oid)s. Clinical investigations and practical recommendations. Drugs. 1997 May;53(5):736–751. doi: 10.2165/00003495-199753050-00002. [DOI] [PubMed] [Google Scholar]
  67. O'Connell D., Koenig A., Jennings S., Hicke B., Han H. L., Fitzwater T., Chang Y. F., Varki N., Parma D., Varki A. Calcium-dependent oligonucleotide antagonists specific for L-selectin. Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5883–5887. doi: 10.1073/pnas.93.12.5883. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Ogawa J., Inoue H., Koide S. Expression of alpha-1,3-fucosyltransferase type IV and VII genes is related to poor prognosis in lung cancer. Cancer Res. 1996 Jan 15;56(2):325–329. [PubMed] [Google Scholar]
  69. Pervin A., Gallo C., Jandik K. A., Han X. J., Linhardt R. J. Preparation and structural characterization of large heparin-derived oligosaccharides. Glycobiology. 1995 Feb;5(1):83–95. doi: 10.1093/glycob/5.1.83. [DOI] [PubMed] [Google Scholar]
  70. Phillips M. L., Nudelman E., Gaeta F. C., Perez M., Singhal A. K., Hakomori S., Paulson J. C. ELAM-1 mediates cell adhesion by recognition of a carbohydrate ligand, sialyl-Lex. Science. 1990 Nov 23;250(4984):1130–1132. doi: 10.1126/science.1701274. [DOI] [PubMed] [Google Scholar]
  71. Phillips M. L., Schwartz B. R., Etzioni A., Bayer R., Ochs H. D., Paulson J. C., Harlan J. M. Neutrophil adhesion in leukocyte adhesion deficiency syndrome type 2. J Clin Invest. 1995 Dec;96(6):2898–2906. doi: 10.1172/JCI118361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Pineo G. F., Hull R. D. Low-molecular-weight heparin: prophylaxis and treatment of venous thromboembolism. Annu Rev Med. 1997;48:79–91. doi: 10.1146/annurev.med.48.1.79. [DOI] [PubMed] [Google Scholar]
  73. Polley M. J., Phillips M. L., Wayner E., Nudelman E., Singhal A. K., Hakomori S., Paulson J. C. CD62 and endothelial cell-leukocyte adhesion molecule 1 (ELAM-1) recognize the same carbohydrate ligand, sialyl-Lewis x. Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):6224–6228. doi: 10.1073/pnas.88.14.6224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Pouyani T., Seed B. PSGL-1 recognition of P-selectin is controlled by a tyrosine sulfation consensus at the PSGL-1 amino terminus. Cell. 1995 Oct 20;83(2):333–343. doi: 10.1016/0092-8674(95)90174-4. [DOI] [PubMed] [Google Scholar]
  75. Powell L. D., Jain R. K., Matta K. L., Sabesan S., Varki A. Characterization of sialyloligosaccharide binding by recombinant soluble and native cell-associated CD22. Evidence for a minimal structural recognition motif and the potential importance of multisite binding. J Biol Chem. 1995 Mar 31;270(13):7523–7532. doi: 10.1074/jbc.270.13.7523. [DOI] [PubMed] [Google Scholar]
  76. Ridings P. C., Holloway S., Bloomfield G. L., Phillips M. L., Fisher B. J., Blocher C. R., Sugerman H. J., Fowler A. A., 3rd Protective role of synthetic sialylated oligosaccharide in sepsis-induced acute lung injury. J Appl Physiol (1985) 1997 Feb;82(2):644–651. doi: 10.1152/jappl.1997.82.2.644. [DOI] [PubMed] [Google Scholar]
  77. Rosen S. D., Bertozzi C. R. The selectins and their ligands. Curr Opin Cell Biol. 1994 Oct;6(5):663–673. doi: 10.1016/0955-0674(94)90092-2. [DOI] [PubMed] [Google Scholar]
  78. Rosen S. D., Bertozzi C. R. Two selectins converge on sulphate. Leukocyte adhesion. Curr Biol. 1996 Mar 1;6(3):261–264. doi: 10.1016/s0960-9822(02)00473-6. [DOI] [PubMed] [Google Scholar]
  79. Roux L., Holojda S., Sundblad G., Freeze H. H., Varki A. Sulfated N-linked oligosaccharides in mammalian cells. I. Complex-type chains with sialic acids and O-sulfate esters. J Biol Chem. 1988 Jun 25;263(18):8879–8889. [PubMed] [Google Scholar]
  80. Sako D., Chang X. J., Barone K. M., Vachino G., White H. M., Shaw G., Veldman G. M., Bean K. M., Ahern T. J., Furie B. Expression cloning of a functional glycoprotein ligand for P-selectin. Cell. 1993 Dec 17;75(6):1179–1186. doi: 10.1016/0092-8674(93)90327-m. [DOI] [PubMed] [Google Scholar]
  81. Sakuragawa N., Takahashi K. Comparative studies on properties of unfractionated and low molecular weight heparin. Semin Thromb Hemost. 1990 Oct;16 (Suppl):5–11. [PubMed] [Google Scholar]
  82. Salzman E. W., Rosenberg R. D., Smith M. H., Lindon J. N., Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest. 1980 Jan;65(1):64–73. doi: 10.1172/JCI109661. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Seekamp A., Ward P. A. Ischemia-reperfusion injury. Agents Actions Suppl. 1993;41:137–152. [PubMed] [Google Scholar]
  84. Skinner M. P., Fournier D. J., Andrews R. K., Gorman J. J., Chesterman C. N., Berndt M. C. Characterization of human platelet GMP-140 as a heparin-binding protein. Biochem Biophys Res Commun. 1989 Nov 15;164(3):1373–1379. doi: 10.1016/0006-291x(89)91821-4. [DOI] [PubMed] [Google Scholar]
  85. Skinner M. P., Lucas C. M., Burns G. F., Chesterman C. N., Berndt M. C. GMP-140 binding to neutrophils is inhibited by sulfated glycans. J Biol Chem. 1991 Mar 25;266(9):5371–5374. [PubMed] [Google Scholar]
  86. Skurk C., Buerke M., Guo J. P., Paulson J., Lefer A. M. Sialyl Lewisx-containing oligosaccharide exerts beneficial effects in murine traumatic shock. Am J Physiol. 1994 Dec;267(6 Pt 2):H2124–H2131. doi: 10.1152/ajpheart.1994.267.6.H2124. [DOI] [PubMed] [Google Scholar]
  87. Sobel B. E. Heparin and streptokinase. Cardiovasc Drugs Ther. 1997 Apr;11(2):97–100. doi: 10.1023/a:1007772412098. [DOI] [PubMed] [Google Scholar]
  88. Springer T. A. Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Annu Rev Physiol. 1995;57:827–872. doi: 10.1146/annurev.ph.57.030195.004143. [DOI] [PubMed] [Google Scholar]
  89. Takada A., Ohmori K., Yoneda T., Tsuyuoka K., Hasegawa A., Kiso M., Kannagi R. Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium. Cancer Res. 1993 Jan 15;53(2):354–361. [PubMed] [Google Scholar]
  90. Tedder T. F., Steeber D. A., Chen A., Engel P. The selectins: vascular adhesion molecules. FASEB J. 1995 Jul;9(10):866–873. [PubMed] [Google Scholar]
  91. Tojo S. J., Yokota S., Koike H., Schultz J., Hamazume Y., Misugi E., Yamada K., Hayashi M., Paulson J. C., Morooka S. Reduction of rat myocardial ischemia and reperfusion injury by sialyl Lewis x oligosaccharide and anti-rat P-selectin antibodies. Glycobiology. 1996 Jun;6(4):463–469. doi: 10.1093/glycob/6.4.463. [DOI] [PubMed] [Google Scholar]
  92. Tyrrell D., James P., Rao N., Foxall C., Abbas S., Dasgupta F., Nashed M., Hasegawa A., Kiso M., Asa D. Structural requirements for the carbohydrate ligand of E-selectin. Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10372–10376. doi: 10.1073/pnas.88.22.10372. [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Varki A., Kornfeld S. The spectrum of anionic oligosaccharides released by endo-beta-N-acetylglucosaminidase H from glycoproteins. Structural studies and interactions with the phosphomannosyl receptor. J Biol Chem. 1983 Mar 10;258(5):2808–2818. [PubMed] [Google Scholar]
  94. Varki A. Selectin ligands. Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7390–7397. doi: 10.1073/pnas.91.16.7390. [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Varki A. Selectin ligands: will the real ones please stand up? J Clin Invest. 1997 Jan 15;99(2):158–162. doi: 10.1172/JCI119142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  96. Vestweber D. Ligand-specificity of the selectins. J Cell Biochem. 1996 Jun 15;61(4):585–591. doi: 10.1002/(SICI)1097-4644(19960616)61:4%3C585::AID-JCB12%3E3.0.CO;2-F. [DOI] [PubMed] [Google Scholar]
  97. Walz G., Aruffo A., Kolanus W., Bevilacqua M., Seed B. Recognition by ELAM-1 of the sialyl-Lex determinant on myeloid and tumor cells. Science. 1990 Nov 23;250(4984):1132–1135. doi: 10.1126/science.1701275. [DOI] [PubMed] [Google Scholar]
  98. Weis W. I., Drickamer K., Hendrickson W. A. Structure of a C-type mannose-binding protein complexed with an oligosaccharide. Nature. 1992 Nov 12;360(6400):127–134. doi: 10.1038/360127a0. [DOI] [PubMed] [Google Scholar]
  99. Weyrich A. S., Ma X. Y., Lefer D. J., Albertine K. H., Lefer A. M. In vivo neutralization of P-selectin protects feline heart and endothelium in myocardial ischemia and reperfusion injury. J Clin Invest. 1993 Jun;91(6):2620–2629. doi: 10.1172/JCI116501. [DOI] [PMC free article] [PubMed] [Google Scholar]
  100. White H. D. Is heparin of value in the management of acute myocardial infarction? Cardiovasc Drugs Ther. 1997 Apr;11(2):111–119. doi: 10.1023/a:1007776613006. [DOI] [PubMed] [Google Scholar]
  101. Wilkins P. P., McEver R. P., Cummings R. D. Structures of the O-glycans on P-selectin glycoprotein ligand-1 from HL-60 cells. J Biol Chem. 1996 Aug 2;271(31):18732–18742. doi: 10.1074/jbc.271.31.18732. [DOI] [PubMed] [Google Scholar]
  102. Wilkins P. P., Moore K. L., McEver R. P., Cummings R. D. Tyrosine sulfation of P-selectin glycoprotein ligand-1 is required for high affinity binding to P-selectin. J Biol Chem. 1995 Sep 29;270(39):22677–22680. doi: 10.1074/jbc.270.39.22677. [DOI] [PubMed] [Google Scholar]
  103. Yednock T. A., Stoolman L. M., Rosen S. D. Phosphomannosyl-derivatized beads detect a receptor involved in lymphocyte homing. J Cell Biol. 1987 Mar;104(3):713–723. doi: 10.1083/jcb.104.3.713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  104. Yoshino K., Ohmoto H., Kondo N., Tsujishita H., Hiramatsu Y., Inoue Y., Kondo H. Studies on selectin blockers. 4. Structure-function relationships of sulfated sialyl Lewis X hexasaccharide ceramides toward E-, P-, and L-selectin binding. J Med Chem. 1997 Feb 14;40(4):455–462. doi: 10.1021/jm9605290. [DOI] [PubMed] [Google Scholar]
  105. Yuen C. T., Bezouska K., O'Brien J., Stoll M., Lemoine R., Lubineau A., Kiso M., Hasegawa A., Bockovich N. J., Nicolaou K. C. Sulfated blood group Lewis(a). A superior oligosaccharide ligand for human E-selectin. J Biol Chem. 1994 Jan 21;269(3):1595–1598. [PubMed] [Google Scholar]
  106. Zakrzewicz A., Gräfe M., Terbeek D., Bongrazio M., Auch-Schwelk W., Walzog B., Graf K., Fleck E., Ley K., Gaehtgens P. L-selectin-dependent leukocyte adhesion to microvascular but not to macrovascular endothelial cells of the human coronary system. Blood. 1997 May 1;89(9):3228–3235. [PubMed] [Google Scholar]
  107. Zimmerman G. A., McIntyre T. M., Prescott S. M. Adhesion and signaling in vascular cell--cell interactions. J Clin Invest. 1996 Oct 15;98(8):1699–1702. doi: 10.1172/JCI118967. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES